Semaglutide, a weight-loss drug, may provide a promising option for patients with obesity and cardiovascular disease by lowering the risk of heart attack, stroke , or death. To assess this potential, a study examined the potential of semaglutide to reduce the risk of heart attack, stroke, or death in patients with obesity and cardiovascular disease without diabetes in over 21,000 adults. The study found that patients taking semaglutide, experienced a 57% greater reduction in heart-related risks compared to those taking tirzepatide.
Even when including patients who paused treatment for more than 30 days, semaglutide users still had a 29% lower risk of heart attack, stroke, or death. These findings suggest that treatment with semaglutide may be associated with a lower risk of heart attack, stroke, or death in patients with obesity and cardiovascular disease, highlighting potential…
